Helix BioPharma Corp.
TSX:HBP.TO · Toronto Stock Exchange
-$0.07 today
Vol 0.00M · Avg 0.00M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $2.8M |
| Receivables | $28.0K |
| Other Current | $122.0K |
| Total Current Assets | $3.0M |
| PP&E (Net) | $1.0K |
| Intangible Assets | $18.4M |
| Total Non-current Assets | $18.4M |
| Total Assets | $21.4M |
Analysis
Selected assets total $21.4M for Latest. The largest visible component is Intangible Assets at $18.4M, about 86.0% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $65.0K -94.0% | $1.1M +33.8% | $808.0K -75.2% | $3.3M -8.8% | $3.6M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 | $0 | $0 | $0 | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $121.0K +124.1% | $54.0K -12.9% | $62.0K -77.8% | $279.0K -21.0% | $353.0K | $533.8M | $399.4M | -$1.7B |
| Inventory | $0 | $0 | $0 -100.0% | $164.0K | $0 | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $223.0K | $0 | $0 | $0 | $0 | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $409.0K -71.9% | $1.5M +46.2% | $996.0K -73.0% | $3.7M -8.0% | $4.0M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $4.0K -87.9% | $33.0K +0.0% | $33.0K -5.7% | $35.0K -25.5% | $47.0K | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $18.4M +1838800.0% | $1.0K | $0 | $0 | $0 | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $0 +100.0% | -$1.0K | $0 | $0 -100.0% | $0 | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $18.4M +55636.4% | $33.0K +0.0% | $33.0K -5.7% | $35.0K -25.5% | $47.0K | -$15.3B | $14.8B | $11.3B |
| Total Assets | $18.8M +1162.7% | $1.5M +44.7% | $1.0M -72.4% | $3.7M -8.2% | $4.1M | $13.3B | $11.9B | $10.6B |
| Account Payables | $0 -100.0% | $855.0K +73.4% | $493.0K -17.7% | $599.0K -59.1% | $1.5M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $335.0K | $0 | $0 -100.0% | $2.5M +21.7% | $2.0M | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 -100.0% | $345.0K | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $2.9M | $0 -100.0% | $998.0K +99900.0% | -$1.0K | $0 | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $3.2M +103.7% | $1.6M -15.7% | $1.9M -45.1% | $3.4M -12.0% | $3.9M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 | $0 -100.0% | $1.6M | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $0 | $0 | $0 | $0 | $0 | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $0 | $0 +100.0% | -$1.0K | $0 -100.0% | $1.6M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $3.2M +103.7% | $1.6M -15.7% | $1.9M -45.1% | $3.4M -37.5% | $5.5M | $14.7B | $3.7B | $9.6B |
| Common Stock | $179.3M +13.1% | $158.6M +4.3% | $152.1M +3.1% | $147.5M +5.6% | $139.7M | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$215.9M -2.5% | -$210.7M -4.6% | -$201.4M -3.2% | -$195.1M -3.5% | -$188.6M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $3.9M -16.7% | $4.6M +6.7% | $4.4M -57.8% | $10.3M -47.4% | $19.6M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 -100.0% | $4.6M | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $15.6M +17417.8% | -$90.0K +89.3% | -$844.0K -364.6% | $319.0K +122.9% | -$1.4M | $9.1B | $7.7B | $3.3B |
| Total Debt | $335.0K | $0 | $0 -100.0% | $2.5M -31.7% | $3.6M | $724.2M | $410.6M | $399.4M |
| Net Debt | $270.0K +125.0% | -$1.1M -33.8% | -$808.0K -3.1% | -$784.0K -1768.1% | $47.0K | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Quipt Home Medical Corp.
QIPT.TO
$221.44M
Cannara Biotech Inc.
LOVE.V
$181.03M
Cardiol Therapeutics Inc.
TSX:CRDL.TO
$171.76M
Cybin Inc.
CYBN.NE
$157.10M
HLS Therapeutics Inc.
TSX:HLS.TO
$133.86M
Jushi Holdings Inc.
JUSH.CN
$133.80M
Satellos Bioscience Inc.
TSX:MSCL.TO
$125.68M
Sernova Corp.
TSX:SVA.TO
$53.90M
Resverlogix Corp.
RVX.TO
$31.70M
Medicenna Therapeutics Corp.
MDNA.TO
$29.90M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does HBP.TO have?
Helix BioPharma Corp. (HBP.TO) reported $65,000.00 in cash and equivalents in fiscal 2025.
How much debt does HBP.TO carry?
Helix BioPharma Corp. (HBP.TO) reported $335,000.00 of total debt, with net debt of $270,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.